Plus Therapeutics, Inc. (PSTV)
- GlobeNewswire
Plus Therapeutics Announces New Employment Inducement Grants
AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr. Huang to induce him to commence emp
- GuruFocus.com
Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
Explore key financial shifts, strategic acquisitions, and clinical advancements as PSTV navigates its Q1 2024 landscape.
- GlobeNewswire
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a cl
